TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial

Aziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, Karine Le Malicot, Simon Pernot, Christophe Louvet, Pascal Artru, Valérie Le Brun Ly, Kaïs Aldabbagh, Faiza Khemissa-Akouz, Thierry Lecomte, H. Castanie, Margot Laly, Damien Botsen, Gaël S. Roth, Emmanuelle Samalin, Marie Müller, Gilles Breysacher, Sylvain Manfrédi, Jean-Marc Phelip, Julien Taı̈eb